The Pathophysiology of Anorexia Nervosa in Hypothalamic Endocrine Function and Bone Metabolism

Received 08/20/2021

Review began 09/17/2021

Review ended 12/07/2021

Published 12/20/2021

© Copyright 2021

Jada et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Keji Jada ¹, Sandrine Kakieu Djossi ¹, Anwar Khedr ², Bandana Neupane ¹, Ekaterina Proskuriakova ², Jihan A. Mostafa ³

¹. Research, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA ². Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA ³. Psychiatry, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA

Corresponding author: Keji Jada, kwajokkeji@gmail.com

Abstract

Anorexia nervosa (AN) is a persistent psychiatric disorder that is marked by abnormal reduced weight and amenorrhea, which may be primary or secondary. AN affects multiple endocrine axes such as gonadal, thyroid, and adrenal axis, growth hormone, and insulin-like growth factor-1, adipokines such as leptin, gut peptides like ghrelin, peptide YY, and amylin. As a result of these changes bone mineral density is reduced, which increases the risk of bone fracture in patients. In this review, we focus on substantial endocrine alterations in AN with a particular emphasis on the severe bone loss associated with this condition and current bone therapies. The disorder primarily affects girls and women, who are the focus of this review. Although the majority of AN-related endocrinopathies improve over time, long-term consequences such as short stature, osteoporosis, and infertility may occur. To avoid serious consequences, nutrition therapy in these patients requires a full understanding of bone complications, and new therapeutic options for treatment should be researched.

Categories: Internal Medicine, Neurology, Psychiatry

Keywords: leptin and ghrelin, hypothalamic gonadal axis, hypothalamic thyroid axis, hypothalamic adrenal axis, hypothalamic endocrine function, amenorrhea, bone metabolism, endocrinopathies, anorexia nervosa

Introduction And Background

Anorexia nervosa (AN) is a psychiatric condition characterized by an eating disorder with endocrine dysfunction. It mainly affects females during adolescence and its etiology is not yet clear or known. The prevalence of this condition among adolescents is around 1% with an annual incidence of new cases 10/100,000 between the ages of 15 and 19. The main characteristics of anorexia are underfeeding and fear of being overweight [1]. Patients attempt to maintain a below-normal weight by several means like vomiting after a meal, following a strict and unrealistic diet, use of diuretics, laxatives or enemas, starvation, and/or strenuous exercise. AN affects bones and the pituitary glands negatively due to starvation and malnutrition [2].

Also, several hormonal changes occur including somatotropin resistance with low insulin-like growth factor-1 (IGF-1) levels, hypothalamic hypogonadism, relative hypercortisolemia, and changes in appetite-regulating hormones including leptin, ghrelin, and peptide YY (PYY). These contribute to abnormalities in bone metabolism resulting in low bone mass, impaired bone microarchitecture, and increased risk for fracture. They also negatively impact cognition, emotions, and mood. As AN affects women predominantly, amenorrhea is one of its serious complications [3]. We have summarized potential symptoms and complications of AN in multiple organs in Figure 1.

How to cite this article

Jada K, Djossi S, Khedr A, et al. (December 20, 2021) The Pathophysiology of Anorexia Nervosa in Hypothalamic Endocrine Function and Bone Metabolism. Cureus 13(12): e20548. DOI 10.7759/cureus.20548

FIGURE 1: Effect of anorexia nervosa in multiple organs

Physiological estrogen replacement should be used to improve bone resorption rates and measures of trait anxiety in adolescents with AN. The best strategy is to boost all biological outcomes such as a menstrual recovery and an electrolyte repletion for profound malnutrition and dehydration for weight gain. Other medications examined to improve bone results include testosterone and IGF-1 replacement, dehydroepiandrosterone (DHEA) with oral estrogen-progesterone combination tablets, bisphosphonates and teriparatide [3].

Although AN was first described centuries ago, the associated risk factors and etiology remain poorly understood and there is little data about it [4]. This article aims to debate the hormonal and bone disturbances that occur due to AN and possible therapeutic approaches for better outcomes and methods for low bone mineral density (BMD).

Review

Hypothalamic-pituitary-gonadal axis

The most well-known endocrine complication of AN is amenorrhea which can be primary or secondary. Hypothalamic amenorrhea is believed to be caused by decreased energy availability in anorexic patients. In previous years, amenorrhea was a significant diagnostic criterion for AN, but because vulnerability to neuroendocrine dysregulation is exceedingly varied, the DSM-5 criteria no longer include amenorrhea as a crucial factor of the diagnosis acknowledging that many women with all the psychiatric features of anorexia and extremely low weight have regular menstrual cycles [1].

In 1974 Boyar et al. published an article in which he described multiple dysregulated luteinizing hormone (LH) pulsatility patterns in amenorrheic women with AN. The patient's LH pulsatile secretion resembled prepubertal or early pubertal girls with either exceptionally low pulse amplitude or increased during sleep. Studies at that time focused on the role of leptin as a regulator of gonadotrophin-releasing hormone pulsatility, which was thought to be responsible for amenorrhea in women with AN [5].

Some studies focused on kisspeptin (an endogenous ligand for the hypothalamic kisspeptin receptor) and its inactivating mutations that lead to pubertal failure. Kisspeptin has been observed to exhibit gonadotropin release in women with hypothalamic amenorrhea but there has been no research specifically examining its effect on AN [6].

Although weight loss usually precedes amenorrhea, some patients experience amenorrhea before weight loss and others reach an extremely low weight while still having a reproductive function [7]. This variation is likely due to individual variances in psychologic stressors, physical activity, fat mass, and leptin levels, resulting in a wide range of threshold weights required for ovulatory function [8,9]. Hypothalamic

amenorrhea causes hypoandrogenemia and hypoestrogenemia in women with AN with a further decline in free testosterone levels in women who use oral contraceptives. These conclusions were discovered when a group of women with AN was compared to healthy controls [10]. It made sense because the ovaries secrete roughly 60% of testosterone in women of reproductive age whereas the adrenal precursors produced 40% [11]. Furthermore, investigations in adults found no decrease in the adrenal-derived prohormone dehydroepiandrosterone sulfate (DHEAS) compared to lean controls even though DHEA levels are generally stimulated by cosyntropin [10].

In contrast, compared to a laboratory-generated normal range, DHEAS levels in adolescent girls were shown to be low. If any, the effect of a relative androgen deficiency in women with AN remains unknown. Nonetheless, they may result in muscle or bone mass loss and adverse mood effects [12].

According to some studies, androgen levels have an inverse association with the degree of depression and anxiety symptoms in women with AN regardless of weight suggesting that relative androgen deficit may contribute to the severity of mood-related symptoms in these individuals. Low-dose testosterone in replacement dosages has been shown to have favorable mood effects in different adult female populations with few adverse effects. Thus, low-dose androgen treatment alone or in conjunction with other medicines may be a beneficial treatment strategy for managing mood comorbidities in women with AN but more research is needed [13].

The growth hormone (GH) insulin-like growth factor-1 (IGF-1) axis

In AN, high GH and low IGF-I levels indicate a nutritionally mediated acquired resistance to GH. Low amounts of GH-binding protein have also been reported. Refeeding can help to reverse abnormalities in the GH-IGF-I axis [14,15].

According to a deconvolutional analysis of GH pulse investigations in adolescents and adults, raised basal secretory rates and higher frequency of secretory bursts underpin the GH excess in AN [15]. These studies discovered a negative relationship between GH secretion and nutritional status markers as body mass index (BMI), fat mass, and leptin. Because acute fasting inhibits the liver's synthesis of IGF-I, GH excess in AN can be related in part to a lack of IGF-I-mediated negative feedback due to low IGF-I levels.

Hypothalamic abnormalities leading to excessive GH due to low somatostatinergic tone or high GH-releasing hormone have also been reported [16]. Muscle atrophy, growth failure, and bone loss are all possible consequences of GH resistance. Anabolic effects of GH on bone are direct and indirect (through IGF-I). The only medication that has been demonstrated to improve BMD in women with AN is recombinant human IGF-I; however, it is not yet permitted for this use [17].

Hypothalamic-pituitary-thyroid axis

In people with AN, hypothyroidism symptoms such as bradycardia, hypothermia, hypotension, dry skin, and a slowed metabolic rate are prevalent. Due to defective peripheral conversion, anorexic patients have a similar biochemical constellation of thyroid hormone abnormalities to a sick euthyroid syndrome with low triiodothyronine (T3) levels and low to normal thyroxine (T4) levels. Thyroid-stimulating hormone levels are usually normal to slightly below average in AN patients [18]. These patients are not considered hypothyroid despite evidence of peripheral thyroid hormone shortage as evidenced by a delayed Achilles reflex half-relaxation time and subsequent improvements with exogenous T3 [19].

Thyroid hormone levels are altered for a variety of reasons in people with AN. In anorexia, like in any chronic disease or starvation, peripheral deiodination of T4 to T3 is reduced and conversion to inactive reverse T3 is enhanced [20]. The hypothalamic release of thyrotropin-releasing hormone may be suppressed in AN resulting in a weak thyroid-stimulating hormone response to low peripheral thyroid hormone levels [19]. A normal or delayed response in thyroid-stimulating hormone can be caused by exogenous thyrotropin-releasing hormone and this delay reverses with weight gain [21]. Malnutrition followed by low IGF-1 levels is most likely the cause of thyroid atrophy in AN. Thyroid atrophy may increase depressive feelings and continued hunger in anorexic patients who have a smaller overall thyroid volume than age-matched control participants. [22].

As previously stated, the biochemical thyroid abnormalities were seen in AN usually resolve with weight gain. But unfortunately, gaining weight by itself will not alleviate psychological issues or personality attributes. Thyroid disease is not the primary cause of psychological disorder although it can exacerbate pre-existing psychological difficulties [23].

Hypothalamic-pituitary-adrenal axis

In AN, plasma cortisol levels rise regardless of whether urinary-free cortisol levels are elevated or normal [24]. According to Weiner in his study, there is evidence that the low T3 syndrome has been shown to lengthen cortisol's half-life in plasma by delaying its metabolic clearance. Also, the HPA appears to be activated as well. The cortisol production rate is considerably raised in AN and the number of secretory

episodes of cortisol is increased when calculated for body mass and body surface area [25]. As a result, when dexamethasone is given to anorexic patients, their plasma cortisol levels are partially suppressed like that observed in patients with depression and Cushing's disease. HPA activation is unknown; however, increased synthesis of corticotropin-releasing hormone (CRH) or hypersensitivity of adrenal cortical cells to CRH stimulation is thought to be among the possibilities [26].

Recently Foppiani et al. demonstrated that desmopressin does not stimulate adrenocorticotrophic hormone (ACTH) and cortisol in AN patients. This could be linked to the downregulation of hypophyseal 1-deamino-8D-arginine vasopressin (DDAVP) V3 receptors in AN [27]. The dexamethasone test has no medical significance in acute AN conditions however, it may have predictive value in individuals who are regaining weight [28]. Refeeding studies of anorexic patients have indicated that weight gains of as little as 10% are related to the normalization of cortisol levels regardless of the initial weight [27].

Adipokines and appetite-regulating hormones

In AN, adipokines like adiponectin and leptin (an anorexigenic hormone) are disrupted as are other appetite-regulating hormones including ghrelin (orexigenic) and PYY. Because of reduced basal leptin secretion and pulse amplitude, people with AN have low leptin levels. Adequate leptin concentrations allow the hypothalamic-pituitary-gonadal axis to function normally and reduced leptin levels in AN may lead to inadequate gonadotropin production [29]. Women with AN with higher fat mass and leptin levels are more likely to have menstruation than women with AN and similar weight despite their low weight. Systemic leptin promotes bone growth especially in appendicular and cortical bone whereas central leptin affects axial trabecular bone due to its effects on the sympathetic nervous system. Decreased leptin levels have been linked to lower bone formation indicators and BMD in healthy populations and AN patients. Compared to a normal-weight population, adiponectin levels are higher, constant, or lower in AN. These variations could be due to various assays identifying distinct circulating adiponectin isoforms as the proportion of lower-molecular-weight adiponectin to total levels in AN is higher than in controls [30].

Ghrelin promotes the production of GH and ACTH while decreasing the production of LH and follicle-stimulating hormone. In adults and adolescents with AN, increased basal secretion and secretory pulse amplitude boost ghrelin levels. Higher ghrelin levels are a suitable adaptation to drive food intake during hunger, produce more elevated GH and cortisol release, and decrease gonadotropin secretion. Ghrelin may also have anabolic effects on the bones. Increased ghrelin levels predict higher BMD in healthy adolescents but not in AN suggesting ghrelin resistance in AN [29].

Although some studies in adults find unchanged or reduced levels of PYY (an anorexigenic hormone), PYY levels are higher in adults and adolescents with AN compared to controls. Higher PYY levels are associated with lower fat mass. PYY can influence gonadotropin secretion and is detrimental to osteoblast function. Higher PYY levels are linked to lower bone turnover markers in adolescents with AN and lower BMD in adults [31].

Central peptides changes in anorexia nervosa

It has been suggested but not definitively proven that peptide changes, even when caused by malnutrition or abnormal eating habits, may have a role in the origin and maintenance of some clinical elements of AN altering the course and prognosis. Tortorella et al. focused on the physiology of central and peripheral peptides that significantly impact eating behavior, body weight, and energy homeostasis in AN patients [32]. In Table 1, we highlight some of the changes in central peptides that regulate eating behavior and energy homeostasis in people with AN [33-41].

		Changes in AN		Reference
		Acute Phase (AN)	Weight restored (AN)	
Plasma AGRP		Increased	No Difference	Merle et al. (2011) [33]
Serum BDNF		Decreased	Decreased	Brandys et al. (2011) [34]
Plasma BDNF		Increased		
CSF CRH		Increased	Increased	Hotta et al. (1986) [35]
Plasma Oxytocin		Decreased	ND	Lawson et al. (2012) [36]
CSF TRH		Decreased	Decreased	Lesem et al. (1994) [37]
CSF SRIF	Plasma SRIF	Decreased	ND	Kaye et al. (1988) [38]
		Increased		
Plasma α-MSH		ND	ND	Moriya et al. [39]
CSF NPY	Plasma	Increased	ND	Sedlackova et al. (2011) [40]
NPY				
CSF Vasopressin	Plasma	ND/Decreased	ND/Decreased	Gold et al. (1983) [41]
Vasopressin		ND/Decreased	ND/Decreased	

TABLE 1: Summary of some of the central peptides changes in AN

AN: Anorexia nervosa; CSF: Cerebrospinal fluid; ND: No difference from healthy controls; Increased: Higher than healthy controls; Decreased: Lower than healthy controls; AGRP: Agouti-related peptide; BDNF: Brain-derived neurotrophic factor; CRH: Corticotropin-releasing hormone; TRH: Thyrotropin-releasing hormone; SRIF: Somatostatin; α-MSH: α-melanocyte-stimulating hormone; NPY: Neuropeptide Y

Bone consequences in anorexia nervosa

Osteopenia is a common and typically long-term complication of AN resulting in clinical fractures and an increased risk of fracture throughout life. A study of women with AN in their mid-twenties found that 55% of them had osteopenia and 35% had osteoporosis, with only 15% having a normal BMD at all skeletal locations studied. In people with AN, the annual rate of loss in BMD at the spine and hip is about 2.5% [42].

A study by Vestergaard et al. described an increase in fracture risk. Reduced markers of bone production and higher markers of resorption have been observed in adults leading to the concept that osteopenia is caused by low osteoblast and high osteoclast activity. On the other hand, AN causes a generalized drop in bone turnover markers during adolescence, which is generally a time of substantial bone turnover [43].

During adolescence, the impact of AN on bone is especially concerning. Adolescence is a period of increasing bone formation as a person approaches peak bone mass, which is a crucial indicator of future bone health and fracture risk. Bone accrual rates are substantially reduced in adolescents with AN resulting in a steady fall in bone density Z-scores [44]. In addition, considerable changes in body weight and composition, pubertal growth, and pubertal hormones such as estradiol and IGF-I occur in anorexic patients impacting bone metabolism [45].

AN affects both cortical and trabecular bone; however, trabecular bone is more severely impacted than cortical possibly reflecting the substantial impact of estrogen deprivation [46]. Dual-energy x-ray absorptiometry (DXA) observations of reduced bone state are corroborated by evaluating bone microarchitecture using ultrahigh-resolution peripheral quantitative computed tomography. The volume and thickness of bone trabecular are reduced in girls but trabecular separation increases. Anorexic patients may experience abnormalities in bone microarchitecture before experiencing changes in BMD [47].

Hypogonadism and later menarchal age are significant contributions to low BMD associated with AN. Estrogen reduces the activity of the receptor activator of nuclear factor k-B ligand (RANKL) and limits the release of proinflammatory cytokines through increasing osteoprotegerin (OPG). Proinflammatory cytokines are prevalent in AN, which may contribute to bone loss. OPG levels are high in AN and are inversely related to BMD despite low estrogen levels [48]. Reduced sclerostin, a product of the *SOST* gene and a glycoprotein released by osteocytes, has also been associated with the effects of estrogen on bone. Sclerostin reduces osteoblast activity by blocking Wnt signaling and increases osteoclasts by boosting RANKL activation of the receptor activator of nuclear factor k-B [49]. Higher sclerostin levels are related to increased bone turnover indicators in controls but this association is interrupted in AN. In anorexic females, physiologic estrogen

replacement improves BMD without affecting sclerostin levels [50]. Other hormones that are affected by AN are displayed in Table 2 [30].

	Levels in Anorexia	Association with bone
Insulin	↓	Low BMD
Amylin	↓	Low BMD
Oxytocin	↓	Low BMD

TABLE 2: Bone anabolic hormones affected by anorexia nervosa

BMD: Bone mineral density; ↓: Decreased

Current treatments for bone disease

Various therapeutic techniques have been investigated for the treatment of bone disease in AN with variable outcomes. In hypogonadal women, estrogen replacement with oral contraceptives makes intuitive sense but there is no proof that exogenous estrogen is genuinely effective.

Although bisphosphonates improve bone density, maintaining a healthy body weight has a more significant long-term impact on bone density. The use of bisphosphonates in young women with AN presents obvious issues as these women may wish to become pregnant once they have recovered and the safety of these medications during pregnancy has yet to be proven. Studies of bisphosphonates have been observed to exhibit improper calcium homeostasis and fetal bone growth in pregnant rats [51].

Menatetrenone (vitamin K2) has shown promise to reduce vertebral bone loss, boost bone formation markers, and decrease bone resorption signs in patients with AN [52]. In those with AN, DHEA levels are abnormally low, which is likely linked to bone loss. Exogenous DHEA use does not significantly increase bone density even though it may improve psychological aspects [12].

Bone development is promoted by recombinant IGF-1, which inhibits bone resorption. It improves bone health in people with GH insufficiency (by stimulating bone metabolism and converting vitamin D to 1,25-dihydroxycholecalciferol) [53]. Recombinant IGF-1 therapy may benefit patients with AN who have a functional GH deficit due to GH resistance. Combining the anabolic capabilities of recombinant IGF-1 with antiresorptive abilities of oral contraceptives has been demonstrated to improve bone density [17].

Nutritional rehabilitation and behavioral support for bodyweight maintenance are essential and should be the cornerstones of AN treatment. Unfortunately, adolescent bone deficiency can lead to a lifelong loss in bone density even if weight is regained [54].

Limitations

There were several limiting factors while we searched for materials for this review. Our data came primarily from open-access articles written in English. Hence, some closed-access articles and articles published in other languages may have been missed.

Conclusions

AN is a primary psychiatric disorder characterized by severe endocrine disorders and severe bone loss. Nutritional rehabilitation usually reverses abnormalities in the adrenal and thyroid glands; nevertheless, there may be long-term consequences such as short stature, infertility, and osteoporosis. Some problems persist after recovery and may contribute to illness progression and relapse. Currently, there are no FDA-approved medications for low BMD treatment in anorexia nervosa; therefore, weight gain and menstruation recovery remain the most effective strategy to increase BMD. In adolescent AN, physiologic estrogen replacement (mostly transdermal) improves BMD and studies are ongoing to assess the influence of IGF-1 replacement on bone density and structure. Further research is essential to better understand the disease's etiology and complications and to find effective treatments for AN and its comorbidities.

Additional Information

Disclosures

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from

any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Milos G, Hebebrand J: Endocrine consequences of anorexia nervosa [Article in German]. *Praxis (Bern 1994)*. 2019, 108:899-904. [10.1024/1661-8157/a003348](#)
2. Usdan LS, Khaodh L, Apovian CM: The endocrinopathies of anorexia nervosa. *Endocr Pract*. 2008, 14:1055-63. [10.4158/EP.14.8.1055](#)
3. Misra M, Klibanski A: Endocrine consequences of anorexia nervosa. *Lancet Diabetes Endocrinol*. 2014, 2:581-92. [10.1016/S2213-8587\(13\)70180-3](#)
4. Keski-Rahkonen A, Hoek HW, Susser ES, et al.: Epidemiology and course of anorexia nervosa in the community. *Am J Psychiatry*. 2007, 164:1259-65. [10.1176/appi.ajp.2007.06081388](#)
5. Boyar RM, Katz J, Finkelstein JW, Kapen S, Weiner H, Weitzman ED, Hellman L: Anorexia nervosa. Immaturity of the 24-hour luteinizing hormone secretory pattern. *N Engl J Med*. 1974, 291:861-5. [10.1056/NEJM197410242911701](#)
6. de Roux N, Genin E, Carel JC, Matsuda F, Chaussain JL, Milgrom E: Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. *Proc Natl Acad Sci U S A*. 2003, 100:10972-6. [10.1073/pnas.1834399100](#)
7. Crisp AH, Stonehill E: Relation between aspects of nutritional disturbance and menstrual activity in primary anorexia nervosa. *Br Med J*. 1971, 3:149-51. [10.1136/bmj.3.5767.149](#)
8. Gendall KA, Joyce PR, Carter FA, McIntosh VV, Jordan J, Bulik CM: The psychobiology and diagnostic significance of amenorrhea in patients with anorexia nervosa. *Fertil Steril*. 2006, 85:1531-5. [10.1016/j.fertnstert.2005.10.048](#)
9. Swenne I: Weight requirements for return of menstruations in teenage girls with eating disorders, weight loss and secondary amenorrhoea. *Acta Paediatr*. 2004, 93:1449-55. [10.1080/08035250410033303](#)
10. Miller KK, Lawson EA, Mathur V, et al.: Androgens in women with anorexia nervosa and normal-weight women with hypothalamic amenorrhea. *J Clin Endocrinol Metab*. 2007, 92:1334-9. [10.1210/jc.2006-2501](#)
11. Judd HL, Lucas WE, Yen SS: Effect of oophorectomy on circulating testosterone and androstenedione levels in patients with endometrial cancer. *Am J Obstet Gynecol*. 1974, 118:793-8. [10.1016/0002-9378\(74\)90490-6](#)
12. Gordon CM, Grace E, Emans SJ, et al.: Effects of oral dehydroepiandrosterone on bone density in young women with anorexia nervosa: a randomized trial. *J Clin Endocrinol Metab*. 2002, 87:4935-41. [10.1210/jc.2002-020545](#)
13. Miller KK, Wexler TL, Zha AM, et al.: Androgen deficiency: association with increased anxiety and depression symptom severity in anorexia nervosa. *J Clin Psychiatry*. 2007, 68:959-65. [10.4088/jcp.v68n0621](#)
14. Støving RK, Chen JW, Glintborg D, Brixen K, Flyvbjerg A, Hørdor K, Frystyk J: Bioactive insulin-like growth factor (IGF) I and IGF-binding protein-1 in anorexia nervosa. *J Clin Endocrinol Metab*. 2007, 92:2323-9. [10.1210/jc.2006-1926](#)
15. Støving RK, Veldhuis JD, Flyvbjerg A, et al.: Jointly amplified basal and pulsatile growth hormone (GH) secretion and increased process irregularity in women with anorexia nervosa: indirect evidence for disruption of feedback regulation within the GH-insulin-like growth factor I axis. *J Clin Endocrinol Metab*. 1999, 84:2056-63. [10.1210/jcem.84.6.5734](#)
16. Gianotti L, Rolla M, Arvat E, et al.: Effect of somatostatin infusion on the somatotrope responsiveness to growth hormone-releasing hormone in patients with anorexia nervosa. *Biol Psychiatry*. 1999, 45:334-9. [10.1016/s0006-3223\(98\)00039-0](#)
17. Grinspoon S, Thomas L, Miller K, Herzog D, Klibanski A: Effects of recombinant human IGF-I and oral contraceptive administration on bone density in anorexia nervosa. *J Clin Endocrinol Metab*. 2002, 87:2883-91. [10.1210/jcem.87.6.8574](#)
18. Miyai K, Yamamoto T, Azukizawa M, Ishibashi K, Kumahara Y: Serum thyroid hormones and thyrotropin in anorexia nervosa. *J Clin Endocrinol Metab*. 1975, 40:334-8. [10.1210/jcem-40-2-334](#)
19. Croxson MS, Ibbertson HK: Low serum triiodothyronine (T3) and hypothyroidism in anorexia nervosa. *J Clin Endocrinol Metab*. 1977, 44:167-74. [10.1210/jcem-44-1-167](#)
20. Moshang T Jr, Parks JS, Baker L, Vaidya V, Utiger RD, Bongiovanni AM, Snyder PJ: Low serum triiodothyronine in patients with anorexia nervosa. *J Clin Endocrinol Metab*. 1975, 40:470-3. [10.1210/jcem-40-3-470](#)
21. Leslie RD, Isaacs AJ, Gomez J, Raggatt PR, Bayliss R: Hypothalamo-pituitary-thyroid function in anorexia nervosa: influence of weight gain. *Br Med J*. 1978, 2:526-8. [10.1136/bmj.2.6136.526](#)
22. Støving RK, Bennedbaek FN, Hegedus L, Hagen C: Evidence of diffuse atrophy of the thyroid gland in patients with anorexia nervosa. *Int J Eat Disord*. 2001, 29:230-5. [10.1002/1098-108x\(200103\)29:2<230::aid-eat1013>3.0.co;2-p](#)
23. Segura-García C, De Fazio P, Sinopoli F, De Masi R, Brambilla F: Food choice in disorders of eating behavior: correlations with the psychopathological aspects of the diseases. *Compr Psychiatry*. 2014, 55:1203-11. [10.1016/j.comppsy.2014.02.013](#)
24. Casper RC, Chatterton RT Jr, Davis JM: Alterations in serum cortisol and its binding characteristics in anorexia nervosa. *J Clin Endocrinol Metab*. 1979, 49:406-11. [10.1210/jcem-49-3-406](#)
25. Weiner H: Psychoendocrinology of anorexia nervosa. *Psychiatr Clin North Am*. 1989, 12:187-206. [10.1016/S0193-953X\(18\)30460-X](#)
26. Gold PW, Gwirtsman H, Avgerinos PC, et al.: Abnormal hypothalamic-pituitary-adrenal function in anorexia nervosa. Pathophysiologic mechanisms in underweight and weight-corrected patients. *N Engl J Med*. 1986, 314:1335-42. [10.1056/NEJM198605223142102](#)
27. Foppiani L, Sessarego P, Valenti S, Falivene MR, Cuttica CM, Giusti Disem M: Lack of effect of desmopressin on ACTH and cortisol responses to ovine corticotropin-releasing hormone in anorexia nervosa. *Eur J Clin*

- Invest. 1996, 26:879-83. [10.1111/j.1365-2362.1996.tb02133.x](#)
28. Estour B, Pugeat M, Lang F, et al.: Rapid escape of cortisol from suppression in response to i.v. dexamethasone in anorexia nervosa. *Clin Endocrinol (Oxf)*. 1990, 33:45-52. [10.1111/j.1365-2265.1990.tb00464.x](#)
 29. Misra M, Miller KK, Kuo K, et al.: Secretory dynamics of leptin in adolescent girls with anorexia nervosa and healthy adolescents. *Am J Physiol Endocrinol Metab*. 2005, 289:E373-81. [10.1152/ajpendo.00041.2005](#)
 30. Misra M, Miller KK, Cord J, et al.: Relationships between serum adipokines, insulin levels, and bone density in girls with anorexia nervosa. *J Clin Endocrinol Metab*. 2007, 92:2046-52. [10.1210/jc.2006-2855](#)
 31. Misra M, Miller KK, Tsai P, et al.: Elevated peptide YY levels in adolescent girls with anorexia nervosa. *J Clin Endocrinol Metab*. 2006, 91:1027-33. [10.1210/jc.2005-1878](#)
 32. Tortorella A, Brambilla F, Fabrazzo M, Volpe U, Monteleone AM, Mastromo D, Monteleone P: Central and peripheral peptides regulating eating behaviour and energy homeostasis in anorexia nervosa and bulimia nervosa: a literature review. *Eur Eat Disord Rev*. 2014, 22:307-20. [10.1002/erv.2303](#)
 33. Merle JV, Haas V, Burghardt R, Döhler N, Schneider N, Lehmkuhl U, Ehrlich S: Agouti-related protein in patients with acute and weight-restored anorexia nervosa. *Psychol Med*. 2011, 41:2183-92. [10.1017/S0033291711000365](#)
 34. Brandys MK, Kas MJ, van Elburg AA, Campbell IC, Adan RA: A meta-analysis of circulating BDNF concentrations in anorexia nervosa. *World J Biol Psychiatry*. 2011, 12:444-54. [10.3109/15622975.2011.562244](#)
 35. Hotta M, Shibasaki T, Masuda A, Imaki T, Demura H, Ling N, Shizume K: The responses of plasma adrenocorticotropin and cortisol to corticotropin-releasing hormone (CRH) and cerebrospinal fluid immunoreactive CRH in anorexia nervosa patients. *J Clin Endocrinol Metab*. 1986, 62:319-24. [10.1210/jcem-62-2-319](#)
 36. Lawson EA, Holsen LM, Santin M, et al.: Oxytocin secretion is associated with severity of disordered eating psychopathology and insular cortex hypoactivation in anorexia nervosa. *J Clin Endocrinol Metab*. 2012, 97:E1898-908. [10.1210/jc.2012-1702](#)
 37. Lesem MD, Kaye WH, Bissette G, Jimerson DC, Nemeroff CB: Cerebrospinal fluid TRH immunoreactivity in anorexia nervosa. *Biol Psychiatry*. 1994, 35:48-53. [10.1016/0006-3223\(94\)91167-3](#)
 38. Kaye WH, Rubinow D, Gwirtsman HE, George DT, Jimerson DC, Gold PW: CSF somatostatin in anorexia nervosa and bulimia: relationship to the hypothalamic pituitary-adrenal cortical axis. *Psychoneuroendocrinology*. 1988, 13:265-72. [10.1016/0306-4530\(88\)90024-8](#)
 39. Moriya J, Takimoto Y, Yoshiuchi K, Shimosawa T, Akabayashi A: Plasma agouti-related protein levels in women with anorexia nervosa. *Psychoneuroendocrinology*. 2006, 31:1057-61. [10.1016/j.psyneuen.2006.06.006](#)
 40. Sedláčková D, Kopečková J, Papežová H, Vybíral S, Kvasničková H, Hill M, Nedvídková J: Changes of plasma obestatin, ghrelin and NPY in anorexia and bulimia nervosa patients before and after a high-carbohydrate breakfast. *Physiol Res*. 2011, 60:165-73. [10.33549/physiolres.931952](#)
 41. Gold PW, Kaye W, Robertson GL, Ebert M: Abnormalities in plasma and cerebrospinal-fluid arginine vasopressin in patients with anorexia nervosa. *N Engl J Med*. 1983, 308:1117-23. [10.1056/NEJM198305123081902](#)
 42. Miller KK, Lee EE, Lawson EA, et al.: Determinants of skeletal loss and recovery in anorexia nervosa. *J Clin Endocrinol Metab*. 2006, 91:2951-7. [10.1210/jc.2005-2818](#)
 43. Vestergaard P, Emborg C, Støvring RK, Hagen C, Mosekilde L, Brixen K: Fractures in patients with anorexia nervosa, bulimia nervosa, and other eating disorders--a nationwide register study. *Int J Eat Disord*. 2002, 32:301-8. [10.1002/eat.10101](#)
 44. Soyka LA, Misra M, Frenchman A, Miller KK, Grinspoon S, Schoenfeld DA, Klibanski A: Abnormal bone mineral accrual in adolescent girls with anorexia nervosa. *J Clin Endocrinol Metab*. 2002, 87:4177-85. [10.1210/jc.2001-011889](#)
 45. Zipfel S, Lowe B, Reas DL, Deter HC, Herzog W: Long-term prognosis in anorexia nervosa: lessons from a 21-year follow-up study. *Lancet*. 2000, 355:721-2. [10.1016/S0140-6736\(99\)05363-5](#)
 46. Grinspoon S, Thomas E, Pitts S, et al.: Prevalence and predictive factors for regional osteopenia in women with anorexia nervosa. *Ann Intern Med*. 2000, 135:790-4. [10.7326/0003-4819-133-10-200011210-00011](#)
 47. Bredella MA, Misra M, Miller KK, et al.: Distal radius in adolescent girls with anorexia nervosa: trabecular structure analysis with high-resolution flat-panel volume CT. *Radiology*. 2008, 249:938-46. [10.1148/radiol.2492080173](#)
 48. Riggs BL: The mechanisms of estrogen regulation of bone resorption. *J Clin Invest*. 2000, 106:1203-4. [10.1172/JCI11468](#)
 49. Li X, Zhang Y, Kang H, et al.: Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. *J Biol Chem*. 2005, 280:19883-7. [10.1074/jbc.M413274200](#)
 50. Faje AT, Fazeli PK, Katzman DK, et al.: Sclerostin levels and bone turnover markers in adolescents with anorexia nervosa and healthy adolescent girls. *Bone*. 2012, 51:474-9. [10.1016/j.bone.2012.06.006](#)
 51. Golden NH, Iglesias EA, Jacobson MS, et al.: Alendronate for the treatment of osteopenia in anorexia nervosa: a randomized, double-blind, placebo-controlled trial. *J Clin Endocrinol Metab*. 2005, 90:3179-85. [10.1210/jc.2004-1659](#)
 52. Iketani T, Kirilke N, Murray, et al.: Effect of menatetrenone (vitamin K2) treatment on bone loss in patients with anorexia nervosa. *Psychiatry Res*. 2003, 117:259-69. [10.1016/s0165-1781\(03\)00024-6](#)
 53. Bianda T, Glatz Y, Bouillon R, Froesch ER, Schmid C: Effects of short-term insulin-like growth factor-I (IGF-I) or growth hormone (GH) treatment on bone metabolism and on production of 1,25-dihydroxycholecalciferol in GH-deficient adults. *J Clin Endocrinol Metab*. 1998, 83:81-7. [10.1210/jcem.83.1.4484](#)
 54. Bruni V, Filicetti MF, Pontello V: Open issues in anorexia nervosa: prevention and therapy of bone loss. *Ann N Y Acad Sci*. 2006, 1092:91-102. [10.1196/annals.1365.008](#)